Bapineuzumab had no health risk found for lower doses but the ones at a higher dose never started, although the efficacy of drugs targeted to brain plaques (neuritic plaques) is being questioned.
Bapineuzumab had no health risk found for lower doses but the ones at a higher dose never started, although the efficacy of drugs targeted to brain plaques (neuritic plaques) is being questioned.